AU1249502A - Diagnosis of pre-eclampsia - Google Patents

Diagnosis of pre-eclampsia

Info

Publication number
AU1249502A
AU1249502A AU1249502A AU1249502A AU1249502A AU 1249502 A AU1249502 A AU 1249502A AU 1249502 A AU1249502 A AU 1249502A AU 1249502 A AU1249502 A AU 1249502A AU 1249502 A AU1249502 A AU 1249502A
Authority
AU
Australia
Prior art keywords
eclampsia
diagnosis
pai
relates
plasminogen activator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU1249502A
Other languages
English (en)
Inventor
Lucilla Poston
Paul Townsend Seed
Beverley Jane Hunt
Lucy Charlotte Chappell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kings College London
Original Assignee
Kings College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kings College London filed Critical Kings College London
Publication of AU1249502A publication Critical patent/AU1249502A/xx
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G01N2333/8132—Plasminogen activator inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU1249502A 2000-11-02 2001-11-02 Diagnosis of pre-eclampsia Pending AU1249502A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0026823.5A GB0026823D0 (en) 2000-11-02 2000-11-02 Diagnosis of pre-eclampsia
PCT/GB2001/004892 WO2002037120A2 (fr) 2000-11-02 2001-11-02 Diagnostic de la pre-eclampsie

Publications (1)

Publication Number Publication Date
AU1249502A true AU1249502A (en) 2002-05-15

Family

ID=9902450

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002212495A Expired AU2002212495B2 (en) 2000-11-02 2001-11-02 Diagnosis of pre-eclampsia
AU1249502A Pending AU1249502A (en) 2000-11-02 2001-11-02 Diagnosis of pre-eclampsia

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2002212495A Expired AU2002212495B2 (en) 2000-11-02 2001-11-02 Diagnosis of pre-eclampsia

Country Status (9)

Country Link
US (3) US7425419B2 (fr)
EP (1) EP1330653B1 (fr)
AT (1) ATE319094T1 (fr)
AU (2) AU2002212495B2 (fr)
CA (1) CA2427645C (fr)
DE (1) DE60117592T8 (fr)
ES (1) ES2256310T3 (fr)
GB (1) GB0026823D0 (fr)
WO (1) WO2002037120A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0312818B8 (pt) 2002-07-19 2021-05-25 Beth Israel Deaconess Medical Ct Inc uso de uma medida do nível do polipeptídeo sflt-1 em uma amostra de uma paciente e uso de uma medida dos níveis de pelo menos dois dos peptídeos sflt1, vegf livre ou polipeptídio pigf livre em uma amostra de um paciente usando um métrico
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
US7335362B2 (en) 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
US7320868B2 (en) * 2004-03-19 2008-01-22 Arieh Gertler Leptin binding domain compositions and methods thereto
AU2005244167A1 (en) * 2004-05-04 2005-11-24 Beth Israel Deaconess Medical Center Methods and compositions for treatment of preeclampsia
US20060067937A1 (en) * 2004-09-24 2006-03-30 Karumanchi S A Methods of diagnosing and treating complications of pregnancy
US7740849B2 (en) 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
DE602005023216D1 (de) * 2004-12-15 2010-10-07 Beth Israel Hospital Nukleinsäuren und polypeptide zur diagnose und behandlung von schwangerschaftskomplikationen
EP2102228A4 (fr) * 2005-09-15 2011-06-01 Limited Dia-Mab Methode de diagnostic de l'eclampsisme
GB0600916D0 (en) 2006-01-17 2006-02-22 Perkinelmer Instr Las Inc detecting and predicting pre-eclampsia
US7790463B2 (en) 2006-02-02 2010-09-07 Yale University Methods of determining whether a pregnant woman is at risk of developing preeclampsia
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
US20080071151A1 (en) * 2006-06-30 2008-03-20 Sogin David C Method and Apparatus for Diagnosing Pre-eclampsia
GB0715030D0 (en) * 2007-08-02 2007-09-12 Wilson Carol J Testing process
EP2245180B1 (fr) * 2008-01-25 2014-06-18 PerkinElmer Health Sciences, Inc. Procédés de détermination du risque de complications prénatales
CA2751679C (fr) 2009-02-06 2018-02-27 Women & Infants' Hospital Of Rhode Island Compositions destinees au traitement de troubles de la grossesse de type preeclampsie renfermant de la transthyretine
GB201013151D0 (en) * 2010-08-04 2010-09-22 Isis Innovation Diagnostic method
EP2790023B1 (fr) * 2011-11-15 2018-07-04 National University Corporation Hamamatsu University School of Medicine Agent thérapeutique et diagnostique contre accouchement précoce ou avortement utilisant un inhibiteur de l'activateur du plasminogène 1
CA2872872A1 (fr) * 2012-05-17 2013-11-21 Universite Laval Marqueurs de prediction precoce de pre-eclampsie
PL3189336T3 (pl) 2014-09-02 2019-07-31 Wallac Oy Sposób określania ryzyka stanu przedrzucawkowego
PL3311158T3 (pl) 2015-06-19 2023-11-27 Sera Prognostics, Inc. Pary biomarkerów do przewidywania przedwczesnego porodu
CA3073192A1 (fr) 2017-08-18 2019-02-21 Sera Prognostics, Inc Proteines d'horloge de grossesse pour prevoir la date et le moment prevus de la naissance
EP4070113A4 (fr) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. Évaluation de la prééclampsie à l'aide de dosages du facteur de croissance placentaire libre et dissocié

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028006A1 (fr) * 1996-12-23 1998-07-02 Cambridge University Technical Services Limited Diagnostic et traitement de grossesses pathologiques

Also Published As

Publication number Publication date
US20040038305A1 (en) 2004-02-26
US7425419B2 (en) 2008-09-16
EP1330653B1 (fr) 2006-03-01
ES2256310T3 (es) 2006-07-16
DE60117592D1 (de) 2006-04-27
US20110300564A1 (en) 2011-12-08
ATE319094T1 (de) 2006-03-15
US8017734B2 (en) 2011-09-13
CA2427645C (fr) 2011-03-08
CA2427645A1 (fr) 2002-05-10
GB0026823D0 (en) 2000-12-20
AU2002212495B2 (en) 2006-04-13
US8283451B2 (en) 2012-10-09
US20090011429A1 (en) 2009-01-08
DE60117592T2 (de) 2006-12-21
DE60117592T8 (de) 2007-05-10
WO2002037120A3 (fr) 2002-10-17
WO2002037120A2 (fr) 2002-05-10
EP1330653A2 (fr) 2003-07-30

Similar Documents

Publication Publication Date Title
AU1249502A (en) Diagnosis of pre-eclampsia
AU3084802A (en) Inflammatory markers as tools in the detection and prevention of diabetes mellitus and as tools to aid in the selection of agents to be used for the prevention and treatment of diabetes
ATE540319T1 (de) Verfahren für die bestimmung von fk506
DE60021068D1 (de) Gewebeinhibitor der matrix-metalproteinase typ 1 (timp-1) als krebsmarker
AU4932099A (en) Methods for fractional quantification of cholesterol in lipoproteins and quantification reagents
DE69936663D1 (de) Zielzellspezifische adenovirale vektoren, die e3 enthalten, und methoden für ihre verwendung
WO2004043223A3 (fr) Compositions et methodes de diagnostic et traitement de la sepsie
MXPA03003682A (es) Metodo para determinar la coagulabilidad y el potencial hemostatico globales.
WO2001055719A3 (fr) Kit de diagnostic permettant de detecter des niveaux de creatine
WO2000033182A3 (fr) Filtrage logiciel predictif de branchement pour microprocesseur
WO2003039491A8 (fr) Nouveaux isoformes de l'inhibiteur de la croissance de cellules endotheliales vasculaires
GB2380544B (en) Method and combined visibility and precipitation measuring instrument for determining visibility, amount of precipitation and type of precipitation
WO2003084384A3 (fr) Diagnostic de l'infection a flavivirus
HK1040429A1 (en) Tau as a marker for early cns damage.
NO20003766L (no) PAI-2 og t-PA som diagnostiske markører for periodontal sykdom
WO2002004952A3 (fr) Methodes diagnostiques et therapeutiques basees sur la molecule d'adhesion l1 pour le traitement d'une tumeur de l'ovaire ou de l'endometre
AU4865997A (en) Monoclonal antibodies against a human act and serine protease complex
DE60126991D1 (de) Verfahren ZUR DIAGNOSE VON SCHIZOPHRENIE
EP1141703A4 (fr) Methodes de determination de risque augmente pour une femme portant un foetus atteint du syndrome de down
GB9723773D0 (en) Haptoglobin assay
AU2002251326A1 (en) Method to analyse the kit genotype of pigs
PL1664330T3 (pl) Badanie krwi i moczu
ATE253223T1 (de) Verfahren und materialien zur diagnose instabiler angina
WO2001096599A3 (fr) Procedes de determination quantitative de b-fibronectine dans des fluides et des tissus biologiques
UA31304A (uk) Спосіб прогнозування тромботичних ускладнень в акушерській практиці